Literature DB >> 35117412

Construction of dysregulated long non-coding RNA-associated competing endogenous RNA network in uterine corpus endometrial carcinoma.

Na Li1, Peng Mi2, Yuanjing Hu1.   

Abstract

BACKGROUND: Competing endogenous RNAs (ceRNAs) render the functions of long non-coding RNAs (lncRNAs) more complicated during cancer processes. Potential lncRNA biomarkers as ceRNAs have not been clearly described for uterine corpus endometrial carcinoma (UCEC). In this research, we researched the functions and regulatory mechanisms of lncRNAs as ceRNAs in UCEC, and their potential applications in prognosis.
METHODS: The lncRNAs, mRNAs, and miRNAs expression profiles including 552 UCEC tissues and 35 non-tumor tissues were downloaded from The Cancer Genome Atlas (TCGA) portal. Differentially expressed mRNAs, miRNAs and lncRNAs were confirmed by R/Bioconductor package of edgeR (|log2FC| >2, FDR <0.01). GO enrichment and KEGG pathway enrichment analyses were accomplished utilizing DAVID online tool. The bioinformatics generated from miRcode and miRTarBase was used to construct the dysregulated lncRNA-associated ceRNA network. Kaplan-Meier curve analysis was used to predict the survival analysis of DERNAs.
RESULTS: A total of 1,102 lncRNAs, 2,612 mRNAs and 189 miRNAs were detected to be dysregulated in UCEC. The newly identified ceRNA network includes 27 UCEC-specific miRNAs, 90 lncRNAs, and 74 mRNAs. Eleven mRNAs, 3 miRNAs (has-mir-425, has-mir-211 and has-mir-301b) and 6 lncRNAs (AC11049.1, ADARB2-AS1, C10orf91, GLIS3-AS1, LINC00237 and LINC00261) were found to be significantly correlated with overall survival in UCEC (P value <0.05).
CONCLUSIONS: In our research process, we successfully constructed a lncRNA-associated ceRNA network which will provide a novel perspective for improving the understanding of UCEC. This study also assists in the identification of new potential biomarkers to be used as candidate prognostic biomarkers or potential therapeutic targets. 2020 Translational Cancer Research. All rights reserved.

Entities:  

Keywords:  The Cancer Genome Atlas (TCGA); Uterus corpus endometrial carcinoma; competing endogenous RNA (ceRNA); integrated bioinformatics

Year:  2020        PMID: 35117412      PMCID: PMC8798494          DOI: 10.21037/tcr.2019.11.44

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


Introduction

Uterine corpus endometrial carcinoma (UCEC), a considerable threat to the health of women all over the world, is stemming from the inner lining cells of the uterus (1,2). The prognosis of UCEC is poor especially in patients who happened recurrence or metastasis after radiotherapy or surgery. Previous studies have attempted to identify tumor biomarkers and have identified multiple UCEC biomarkers, such as activated leukocyte cell adhesion molecule (CAM) (3), L1 CAM, etc. (4). Up to now, there is no way to fully elucidate the pathogenesis of UCEC. Accordingly, identification of personalized treatment strategies is urgently needed, such as potential biomarkers and therapeutic targets. In 2011, Salmena et al. proposed the hypothesis of competing endogenous RNA (ceRNA), which described a complicated post-transcriptional regulatory network. In this network, lncRNAs, mRNAs, and other RNAs can act as natural miRNA sponges, sharing one or more miRNA response elements (MREs) to restrain miRNA function (5). In the last few years, an increasing number of researches have confirmed that the lncRNA-miRNAs-mRNAs regulation network plays a crucial role in pathogenesis and progression of malignant tumors such as breast cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, oral cancer, and thyroid cancer (6-14). Non-coding RNA molecules (ncRNAs) longer than 200 nucleotides (nt) were usually named as long non-coding RNAs (lncRNAs) which distinguished from short-chain ncRNAs (15). LncRNA as ceRNA can compete with miRNAs to regulate the level of the gene encoding protein and participate in regulating the cell biology. MiRNAs have become an indispensable part of the ceRNA network by competition with target mRNA, inhibition of mRNA expression (16). However, a complete genome-wide and large number of samples analysis of regulatory network relating to lncRNA-miRNA-mRNA of UCEC it is still lacking. The current study clarified how the UCEC-related lncRNAs serve as ceRNAs to regulate target genes and is involved in pathogenesis and prognosis of UCEC. The Cancer Genome Atlas (TCGA) is a public dataset that includes widespread and coordinated genome alterations in as many as 33 different types of cancer, which has been applied to collect, select, and analyze genomic changes in all kinds of cancers. As far as we know, ceRNA network of UCEC patients has not been constructed up to now. Therefore, the purpose of this current research was to determine a multi-RNA-based classifier based on the study of the lncRNA, miRNA and mRNA profiles of UCEC patients.

Methods

Data acquisition and selection

RNA expression profiles with clinical information and data were entirely downloaded from TCGA database. For good measure, the level 3 mRNASeq gene expression profiles, miRNAseq data of samples, and clinical data of those patients were downloaded by the Data Transfer Tool (provided by GDC Apps) (https://tcga-data.nci.nih.gov/). The sequencing platforms of the sequenced data were Illumina HiSeq RNASeq and Illumina HiSeq_miRNA-Seq platform. The downloaded data consists of many individual data files, each representing a tissue sample. A total of 552 UCEC samples (cohort T) and 35 normal control samples (cohort N) were included in the dataset. Our research conforms the publication guidelines offered by TCGA (http://cancergenome.nih.gov/publications/ publication guidelines). TCGA dataset collected and processed patients’ genome data under the precondition of abiding by the data access policies which have been authorized by its ethics committee, as a result, our current research did not need further ethical approval.

Differentially expressed analysis

Differential expressed lncRNAs, mRNAs and miRNAs (DElncRNAs, DEmRNAs, DEmiRNAs) between cohort T and cohort N were identified by differentially expression analysis through the R/Bioconductor package of edgeR (R version 3.4.4) (17). The cut-off values were |log2FC| >2 and FDR <0.01 (FC, fold change; FDR, false discovery rate).

Functional enrichment analysis

The function and pathway enrichment analyses were conducted by Database for Annotation, Visualization, and Integrated Discovery (DAVID) bioinformatics resources (https://david.ncifcrf.gov/). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were researched. The criteria were set at P<0.05.

Constructing ceRNA network

MiRcode (http://www.mircode.org/) was used to predict lncRNA-miRNA interactions (18). The mRNAs targeted by miRNAs were predicted cooperatively through TargetScan (http://www.TargetScan.org/mamm_31/), miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/) and miRanda (http://www.Microrna.org/microrna/home.do) (19,20). To better understand how lncRNA mediates mRNA by combining with miRNA in UCEC, a network graph of ceRNA was constructed according to the above data and visualized utilizing Cytoscape v3.6.1. The flowchart of the ceRNA network construction is presented in .
Figure 1

Flowchart of the construction of a ceRNA network. UCEC, uterine corpus endometrial carcinoma; lncRNAs, long non-coding RNAs; miRNAs, microRNAs; ceRNAs, competing endogenous RNA.

Flowchart of the construction of a ceRNA network. UCEC, uterine corpus endometrial carcinoma; lncRNAs, long non-coding RNAs; miRNAs, microRNAs; ceRNAs, competing endogenous RNA.

Survival analysis

To find the prognostic DERs signature, associating the clinical data of those patients with UCEC downloaded from TCGA, the survival curves of those samples with differentially expressed lncRNAs, miRNAs and mRNAs were drawn from using the “survival” package in R. Kaplan-Meier curve analysis was used to predict this univariate survival analysis. P values <0.05 was considered statistically significant.

Results

Identification of DERNAs

The Data Transfer Tool of the TCGA database was used to download RNAs expression profiles of UCEC patients and corresponding clinical information. We identified the significant DElncRNA, DEmRNAs and DEmiRNAs in UCEC samples compared with the normal samples using “edgeR” and limma in R language. As a result, a total of 1,102 lncRNAs, 2,612 mRNAs and 189 miRNAs were detected to be collectively dysregulated in UCEC. Among them, 314 and 788 lncRNAs were popularly upregulated and down-regulated, simultaneously, 1,641 and 971 mRNAs were collectively upregulated and down-regulated, severally. A total of 140 (74.07%) up-regulated and 49 (25.93%) down-regulated DEmiRNAs were identified (). The heat map with complete link-age clustering of DElncRNAs, DEmRNAs and DEmiRNAs was built utilizing the “plots” package in R (data not shown).
Figure 2

Volcano Plot visualizing the DERs which was screened by both limma and edgeR. (A) lncRNA; (B) mRNA; (C) miRNA. The colorized points in scatter plot represent the DERs with statistical significance (adj.P.value <0.05, |logFC| >2). Green and red point represent downregulated and upregulated DERs respectively.

Volcano Plot visualizing the DERs which was screened by both limma and edgeR. (A) lncRNA; (B) mRNA; (C) miRNA. The colorized points in scatter plot represent the DERs with statistical significance (adj.P.value <0.05, |logFC| >2). Green and red point represent downregulated and upregulated DERs respectively.

GO enrichment and KEGG pathway analyses

In order to further study of the functions of the differentially expressed genes (DEGs), we selected differentially expressed mRNAs for analysis. The 2,612 differentially expressed mRNAs were analyzed with DAVID bioinformatics resources. We select to show the top 20 GO biological processes and 20 KEGG pathways of the DEGs on account of the P-values (). Among these pathways, the cAMP, GMP-PKG, Ras signaling pathways and CAMs were confirmed as UCEC-associated pathways.
Figure 3

Top 20 GO terms for intersection mRNAs. GO, Gene Ontology.

Figure 4

Top 20 KEGG pathways for intersection mRNAs. KEGG, Kyoto Encyclopaedia of Genes and Genomes.

Top 20 GO terms for intersection mRNAs. GO, Gene Ontology. Top 20 KEGG pathways for intersection mRNAs. KEGG, Kyoto Encyclopaedia of Genes and Genomes.

ceRNA network in UCEC

For the sake of understand how lncRNA mediates mRNA through combining with miRNA in UCEC, we estimated the potential connections among the above corporately dysregulated genes according to the ceRNA hypothesis through computational analysis. We found that 27 key miRNAs were predicted to target 90 key lncRNAs based on miRcode (). The 27 key miRNAs were then used to predict key mRNAs using Targetscan, miRDB, and miRanda. Seventy-four mRNAs were found to interact with 20 miRNAs (). In the end, the ceRNA network that visualized based on the interactions among lncRNAs, miRNAs and mRNAs using Cytoscape v3.6.1 contained 90 lncRNAs, 27 miRNAs and 74 mRNAs ().
Table 1

miRNAs that may target UCEC lncRNAs

lncRNAmiRNAs
AC002464.1hsa-mir-215, hsa-mir-383
AC020907.1hsa-mir-195, hsa-mir-424, hsa-mir-216b
AC061975.6hsa-mir-106a
AC080037.1hsa-mir-429
AC092422.1hsa-mir-195, hsa-mir-424, hsa-mir-383
AC104472.1hsa-mir-143, hsa-mir-183, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-363, hsa-mir-425, hsa-mir-489
AC107959.1hsa-mir-301b, hsa-mir-122, hsa-mir-383
AC109462.1hsa-mir-301b, hsa-mir-143
AC110491.1hsa-mir-140, hsa-mir-141, hsa-mir-200a, hsa-mir-143, hsa-mir-182, hsa-mir-215, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-205, hsa-mir-216b, hsa-mir-508, hsa-mir-425, hsa-mir-489
AC110619.1hsa-mir-140, hsa-mir-143, hsa-mir-184, hsa-mir-122
AC112721.1hsa-mir-195, hsa-mir-424
AC135178.1hsa-mir-106a, hsa-mir-122, hsa-mir-425, hsa-mir-489
ADAMTS9-AS1hsa-mir-301b, hsa-mir-96, hsa-mir-145, hsa-mir-182
ADAMTS9-AS2hsa-mir-301b, hsa-mir-106a, hsa-mir-96, hsa-mir-140, hsa-mir-141, hsa-mir-200a, hsa-mir-143, hsa-mir-145, hsa-mir-182, hsa-mir-183, hsa-mir-184, hsa-mir-204, hsa-mir-211, hsa-mir-205, hsa-mir-216b, hsa-mir-122, hsa-mir-363
ADARB2-AS1hsa-mir-195, hsa-mir-424, hsa-mir-205, hsa-mir-216b
AGAP11hsa-mir-106a, hsa-mir-141, hsa-mir-200a, hsa-mir-143, hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-182, hsa-mir-204, hsa-mir-211, hsa-mir-205, hsa-mir-216b
AL354707.1hsa-mir-216b
AL356133.2hsa-mir-106a, hsa-mir-383
AL391152.1hsa-mir-143
AL596188.1hsa-mir-205
AL713998.1hsa-mir-141, hsa-mir-200a, hsa-mir-383
ALDH1L1-AS2hsa-mir-301b, hsa-mir-106a, hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-210, hsa-mir-508
ARHGEF38-IT1hsa-mir-143, hsa-mir-425, hsa-mir-489
ATXN8OShsa-mir-145, hsa-mir-183, hsa-mir-204, hsa-mir-211, hsa-mir-205, hsa-mir-210, hsa-mir-122
BOK-AS1hsa-mir-184, hsa-mir-216b
BX255923.1hsa-mir-204, hsa-mir-211, hsa-mir-216b, hsa-mir-363
C10orf91hsa-mir-106a, hsa-mir-140, hsa-mir-143, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-122
C15orf54hsa-mir-301b, hsa-mir-106a, hsa-mir-143, hsa-mir-195, hsa-mir-424, hsa-mir-182, hsa-mir-429
C2orf48hsa-mir-106a, hsa-mir-143, hsa-mir-195, hsa-mir-424, hsa-mir-183, hsa-mir-204, hsa-mir-211, hsa-mir-122
C6orf99hsa-mir-140
C8orf49hsa-mir-301b, hsa-mir-106a, hsa-mir-100, hsa-mir-143, hsa-mir-195, hsa-mir-424, hsa-mir-184, hsa-mir-429, hsa-mir-508, hsa-mir-122, hsa-mir-363
DIO3OShsa-mir-106a, hsa-mir-143, hsa-mir-215, hsa-mir-204, hsa-mir-211, hsa-mir-508, hsa-mir-122, hsa-mir-383
DLEU7-AS1hsa-mir-96, hsa-mir-195, hsa-mir-424, hsa-mir-182, hsa-mir-215
DLX6-AS1hsa-mir-106a, hsa-mir-100, hsa-mir-141, hsa-mir-200a, hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-215, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-216b, hsa-mir-122, hsa-mir-383
DNM3OShsa-mir-301b, hsa-mir-145, hsa-mir-204, hsa-mir-211
DSCR10hsa-mir-195, hsa-mir-424
DSCR4hsa-mir-301b, hsa-mir-145, hsa-mir-216b, hsa-mir-508, hsa-mir-383, hsa-mir-425, hsa-mir-489
DSCR4-IT1hsa-mir-204, hsa-mir-211, hsa-mir-508, hsa-mir-140, hsa-mir-143, hsa-mir-195, hsa-mir-424, hsa-mir-216b
DSCR8hsa-mir-205, hsa-mir-122
ERVMER61-1hsa-mir-96, hsa-mir-182, hsa-mir-204, hsa-mir-211, hsa-mir-205
FAM41Chsa-mir-141, hsa-mir-200a, hsa-mir-145, hsa-mir-183, hsa-mir-205
FRMD6-AS2hsa-mir-96, hsa-mir-143, hsa-mir-182, hsa-mir-184, hsa-mir-204, hsa-mir-211
GLIS3-AS1hsa-mir-100, hsa-mir-140
HAR1Ahsa-mir-216b, hsa-mir-122
JAZF1-AS1hsa-mir-106a, hsa-mir-143, hsa-mir-205, hsa-mir-216b, hsa-mir-363
KCNQ1DNhsa-mir-145, hsa-mir-195, hsa-mir-424
KIAA0087hsa-mir-96, hsa-mir-141, hsa-mir-200a, hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-182, hsa-mir-183, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-383
LINC00028hsa-mir-195, hsa-mir-424, hsa-mir-204, hsa-mir-211, hsa-mir-383
LINC00051hsa-mir-140, hsa-mir-183, hsa-mir-205, hsa-mir-363
LINC00052hsa-mir-145, hsa-mir-216b, hsa-mir-363, hsa-mir-425, hsa-mir-489
LINC00113hsa-mir-145
LINC00211hsa-mir-301b, hsa-mir-183, hsa-mir-184, hsa-mir-204, hsa-mir-211, hsa-mir-216b, hsa-mir-508, hsa-mir-383
LINC00237hsa-mir-143, hsa-mir-205
LINC00261hsa-mir-301b, hsa-mir-140, hsa-mir-143, hsa-mir-145, hsa-mir-182, hsa-mir-183, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-216b, hsa-mir-508
LINC00314hsa-mir-106a, hsa-mir-143, hsa-mir-204, hsa-mir-211, hsa-mir-122
LINC00336hsa-mir-96, hsa-mir-100, hsa-mir-143, hsa-mir-145, hsa-mir-216b
LINC00337hsa-mir-106a, hsa-mir-145, hsa-mir-182, hsa-mir-216b, hsa-mir-383, hsa-mir-143, hsa-mir-205
LINC00355hsa-mir-140, hsa-mir-141, hsa-mir-200a, hsa-mir-195, hsa-mir-424, hsa-mir-122
LINC00393hsa-mir-106a, hsa-mir-215
LINC00443hsa-mir-301b, hsa-mir-141, hsa-mir-200a, hsa-mir-183, hsa-mir-204, hsa-mir-211, hsa-mir-363
LINC00458hsa-mir-141, hsa-mir-200a, hsa-mir-143, hsa-mir-195, hsa-mir-424, hsa-mir-183, hsa-mir-204, hsa-mir-211, hsa-mir-205, hsa-mir-122, hsa-mir-383
LINC00470hsa-mir-140, hsa-mir-141, hsa-mir-200a, hsa-mir-143, hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-429, hsa-mir-216b, hsa-mir-508, hsa-mir-122, hsa-mir-383
LINC00473hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-210
LINC00488hsa-mir-96, hsa-mir-215, hsa-mir-205, hsa-mir-216b, hsa-mir-508, hsa-mir-122
LINC00491hsa-mir-145, hsa-mir-184, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-216b, hsa-mir-122
LINC00494hsa-mir-106a, hsa-mir-143, hsa-mir-145, hsa-mir-182, hsa-mir-210, hsa-mir-508, hsa-mir-383
LINC00523hsa-mir-141, hsa-mir-200a, hsa-mir-215, hsa-mir-508, hsa-mir-122
LSAMP-AS1hsa-mir-183
MAGI2-AS3hsa-mir-106a, hsa-mir-141, hsa-mir-200a, hsa-mir-143, hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-210, hsa-mir-216b, hsa-mir-508, hsa-mir-122, hsa-mir-363, hsa-mir-425, hsa-mir-489
MEG3hsa-mir-301b, hsa-mir-106a, hsa-mir-96, hsa-mir-140, hsa-mir-141, hsa-mir-200a, hsa-mir-143, hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-182, hsa-mir-184, hsa-mir-215, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-205, hsa-mir-216b, hsa-mir-508, hsa-mir-122, hsa-mir-383
MIR205HGhsa-mir-301b, hsa-mir-143, hsa-mir-145, hsa-mir-183, hsa-mir-215, hsa-mir-204, hsa-mir-211, hsa-mir-205, hsa-mir-216b, hsa-mir-122, hsa-mir-383
MIR210HGhsa-mir-106a, hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-182, hsa-mir-216b, hsa-mir-122
MIR7-3HGhsa-mir-145, hsa-mir-204, hsa-mir-211
MYCNOShsa-mir-183, hsa-mir-205, hsa-mir-122, hsa-mir-363
NAALADL2-AS2hsa-mir-183
NAV2-AS2hsa-mir-96, hsa-mir-182, hsa-mir-204, hsa-mir-211, hsa-mir-122
NKX2-1-AS1hsa-mir-301b, hsa-mir-96, hsa-mir-145, hsa-mir-182, hsa-mir-204, hsa-mir-211
NOVA1-AS1hsa-mir-216b, hsa-mir-425, hsa-mir-489
OXCT1-AS1hsa-mir-106a, hsa-mir-195, hsa-mir-424
POU6F2-AS2hsa-mir-383
PRICKLE2-AS1hsa-mir-106a, hsa-mir-141, hsa-mir-200a
PRICKLE2-AS2hsa-mir-145, hsa-mir-122
RERG-IT1hsa-mir-182
RMRPhsa-mir-122
RMSThsa-mir-301b, hsa-mir-96, hsa-mir-145, hsa-mir-195, hsa-mir-424, hsa-mir-182, hsa-mir-429, hsa-mir-204, hsa-mir-211, hsa-mir-205, hsa-mir-508, hsa-mir-363, hsa-mir-425, hsa-mir-489
SOX21-AS1hsa-mir-301b, hsa-mir-425, hsa-mir-489
TBL1XR1-AS1hsa-mir-96, hsa-mir-182, hsa-mir-205
TDRG1hsa-mir-215, hsa-mir-122
TLR8-AS1hsa-mir-140, hsa-mir-182, hsa-mir-204, hsa-mir-211
WARS2-IT1hsa-mir-140, hsa-mir-143, hsa-mir-195, hsa-mir-424, hsa-mir-216b

miRNAs, microRNAs; UCEC, uterine corpus endometrial carcinoma; lncRNAs, long non-coding RNAs.

Table 2

miRNAs that may target UCEC mRNAs

miRNAmRNAs
hsa-mir-106aFAM129A, KATNAL1, KIF23, RRM2, KPNA2, PLS1, ANKRD33B, CFL2HMGB3, E2F1, SALL3, TXNIP
hsa-mir-122AKT3, CLIC4
hsa-mir-140PDGFRA
hsa-mir-141ZEB1, EPHA7, ZEB2
hsa-mir-143IGFBP5, PAPPA
hsa-mir-145ABRACL, FLI1, DDC
hsa-mir-182ULBP2, TCEAL7, RECK, FOXF2, BDNF, NR3C1, MITF, CITED2, THBS1
hsa-mir-183AKAP12, IDH2, NR3C1, ZEB1, CCNB1
hsa-mir-195TGFBR3, WNT7A, AKT3, PSAT1, CEP55, RASSF2, RECK, KATNAL1, FGF2, ITPR1, E2F7, CBX2, RAB23, TPM2, KIF23, PRICKLE2, CLSPN, RUNX1T1, CCNE1, CDC25A
hsa-mir-200aZEB1, ZEB2, EPHA7
hsa-mir-204ZCCHC24, ALPL, ITPR1, PRLR, CHRDL1
hsa-mir-205LRRK2, ZEB1
hsa-mir-210SERTM1
hsa-mir-211POU3F2, ZCCHC24, PRLR, ITPR1, CHRDL1
hsa-mir-216bFZD5, MCM4
hsa-mir-363ITPR1, S1PR1, TEF, SOX11, PAX9, SLC12A5
hsa-mir-424E2F7, GNAL, RAB23, RASSF2, CLSPN, TGFBR3, CEP55, ITPR1, CBX2, CCNE1, RUNX1T1, TPM2, PSAT1, AKT3, RECK, KIF23, FGF2, CDC25A
hsa-mir-425MAP2K6
hsa-mir-429ZFPM2, RASSF8, ZEB1, SHCBP1
hsa-mir-96TRIB3, PROK2, ALK, ZEB1, JAZF1

miRNAs, microRNAs; UCEC, uterine corpus endometrial carcinoma; lncRNAs, long non-coding RNAs.

Figure 5

The lncRNA/miRNA/mRNA ceRNA network. Red balls, upregulated mRNAs; blue balls, downregulated mRNAs; red squares, upregulated miRNAs; blue squares, downregulated miRNAs; red diamonds, upregulated lncRNAs; blue diamonds, downregulated lncRNAs. lncRNAs, long non-coding RNAs; miRNAs, microRNAs; ceRNA, competing endogenous RNA.

miRNAs, microRNAs; UCEC, uterine corpus endometrial carcinoma; lncRNAs, long non-coding RNAs. miRNAs, microRNAs; UCEC, uterine corpus endometrial carcinoma; lncRNAs, long non-coding RNAs. The lncRNA/miRNA/mRNA ceRNA network. Red balls, upregulated mRNAs; blue balls, downregulated mRNAs; red squares, upregulated miRNAs; blue squares, downregulated miRNAs; red diamonds, upregulated lncRNAs; blue diamonds, downregulated lncRNAs. lncRNAs, long non-coding RNAs; miRNAs, microRNAs; ceRNA, competing endogenous RNA.

Survival analyses of DERs

The overall survival for DERs in patients was researched to detect the relationship between differentially expressed RNAs (DERs) and the conditions of prognosis of patients with UCEC. Six of 90 DElncRNAs had a significant association with the overall survival of UCEC patients (P<0.05). As described in , LINC00237 and LINC00261 had positive correlation with overall survival (P<0.05). AC11049.1, ADARB2-AS1, C10orf91 and GLIS3-AS1 were negatively correlated with overall survival (P<0.05). Three DEmiRNAs, has-mir-425, has-mir-211 and has-mir-301b were identified to be related to high levels of DEmiRNAs and with poor prognosis (). Eleven DEmRNAs, including ALK, CCNE1, E2F7, GNAL, KPNA2, NR3C1, RASSF2, RECK, SERTM1, SLC12A5 and SOX11 were found to be associated with overall survival ().
Figure 6

Survival curves for 6 lncRNAs associated with overall survival in UCEC. Six DElncRNAs are presented (P<0.05, including AC11049.1, ADARB2-AS1, C10orf91, GLIS3-AS1, LINC00237 and LINC00261. Horizontal axis: overall survival time: years; vertical axis: survival function). UCEC, uterine corpus endometrial carcinoma.

Figure 7

Survival curves for 3 miRNAs associated with overall survival in UCEC (horizontal axis: overall survival time: years; vertical axis: survival function). UCEC, uterine corpus endometrial carcinoma.

Figure 8

Survival curves for 11 mRNAs associated with overall survival in UCEC. (horizontal axis: overall survival time: years; vertical axis: survival function). UCEC, uterine corpus endometrial carcinoma.

Survival curves for 6 lncRNAs associated with overall survival in UCEC. Six DElncRNAs are presented (P<0.05, including AC11049.1, ADARB2-AS1, C10orf91, GLIS3-AS1, LINC00237 and LINC00261. Horizontal axis: overall survival time: years; vertical axis: survival function). UCEC, uterine corpus endometrial carcinoma. Survival curves for 3 miRNAs associated with overall survival in UCEC (horizontal axis: overall survival time: years; vertical axis: survival function). UCEC, uterine corpus endometrial carcinoma. Survival curves for 11 mRNAs associated with overall survival in UCEC. (horizontal axis: overall survival time: years; vertical axis: survival function). UCEC, uterine corpus endometrial carcinoma.

Discussion

In the last few years, cumulative evidence has indicated that lncRNAs play a vital part during tumor progression and may act as a molecular prognostic indicator and therapeutic target of tumors (21-23). lncRNAs function in many ways. Different studies have showed that the expression of aberrant lncRNAs presents a direction for diagnosis, prognosis, and therapy of different types of cancer (24). The ceRNA hypothesis postulates that lncRNAs may compete with mRNAs for the binding sites of miRNAs and may further affect mRNA expression through MREs (5). The emergence of this hypothesis further complicates the relationship between miRNAs, mRNAs and lncRNAs and better explains the interaction among a variety of types of RNAs at the genetic level. Latest studies have confirmed that the differential expression of lncRNAs is compactly correlated with the pathogenesis and prognosis of tumors, and serve as a tumor-associated predictor (25,26). Zhang et al. demonstrated 7 lncRNAs had remarkable association with overall survival of rectal adenocarcinoma patients (6). Hu et al. accomplished lncRNA expression profiling in large colorectal cancer cohorts from Gene Expression Omnibus database and established a set included six lncRNAs that may be an effective means for evaluating clinical prognosis (27). Although some researches have recognized several lncRNAs displaying upregulated and downregulated expression pattern in UCEC (28-32), these studies focused attention on recognizing differentially expressed lncRNAs. Of late, Zhou et al. (15) reported that 11 independent prognostic lncRNAs (RP11-1072A3.3.1, ACVR2B-AS1, RP4-781 K5.7.1, AC073046.25, AP001347.6, DOCK9-AS2, NRAV, GTF3C2-AS1, LINC01006, RP11-531A24.5 and AC004947.2) had a linear combination which was defined as an innovative lncRNA-focus expression signature to forecast survival of UCEC patients. To the best of our knowledge, no a whole genome-wide analysis of the lncRNA-miRNA-mRNA regulatory network of UCEC involved large number of samples has been reported. In this research, we confirmed UCEC-specific DElncRNAs, mRNAs and miRNAs based on the differential expression between tumor tissues and normal tissues. We successfully constructed lncRNA-miRNAs-mRNA ceRNA network and used it to disclose the interaction between specific lncRNAs and miRNAs and coding genes in UCEC. Compared with the routine samples, ninety DElncRNAs were recognized in UCEC samples. We evaluated the relationship between survival and all the DERs included in the ceRNA network. Finally, 6 lncRNAs, 3 miRNAs and 11 mRNAs were demonstrated to be remarkably associated with overall survival, which may provide meaningful guidance for the prospective research. The low expression of ADARB2-AS1 and high expression of LINC00261 in UCEC tissues may have the potential capacity to improve overall survival. It has been identified that ADARB2-AS1 has prognostic value for breast cancer (33). The decrease of lncRNA LINC00261 expression indicated a poor prognosis in gastric cancer and inhibited gastric cancer metastasis through impacting the transition of epithelial–mesenchymal (34). We analyzed functions and pathways of UCEC-specific mRNAs using GO and KEGG. The GO enrichment analysis revealed that functions involved aspects of cellular functions and metabolism, etc. Several UCEC-associated pathways were confirmed by KEGG pathway analysis. The Ras signaling pathway is constantly varied in multiple different types of cancer, which is an early event driving tumorigenesis that has been observed and have also been connected with poor survival and treatment resistance (35). Saadatmand et al. (24) reported that CAMs play a significant part in the progression of metastasis. Previous studies have confirmed that wnt/β-catenin signaling can be inhibited by activating the cGMP/PKG pathway (36). These pathways and functions identified in our study may also be related to UCEC-specific lncRNAs due to altered interactions between lncRNAs and mRNAs in UCEC. We can further research the potential mechanism of the intersections among lncRNAs, mRNAs and miRNAs with the ceRNA network. Several limitations should be taken into consideration in this research. In the present research, the ceRNA network was constructed by integrating bioinformatics analysis based on the hypothesis that lncRNAs can work as ceRNAs and regulate expression of the target genes through combining with miRNAs. One lncRNA could be in contact with a mass of miRNAs and concerned mRNAs indicated by the ceRNA network. Therefore, more research may concentrate on directing experiments to confirm several considerable interactions, specifically to validate the critical interactions to identify the effect of these lncRNAs as ceRNA in UCEC.

Conclusions

In conclusion, a lncRNA-associated ceRNA network was satisfactorily constructed, and it revealed the relationship among lncRNAs, miRNAs and mRNAs, and aided in elucidating the mechanisms underlying UCEC on the genetic level. In a great quantity of UCEC samples, six lncRNAs which were specific with cancer were recognized from generous candidates lncRNAs. Our study offers innovative DERs which can serve as candidates of prognosis biomarkers or potential therapeutic targets. Obviously, our results still necessitate to be further confirmed by prospective study in multicenter clinical study.
  36 in total

1.  ElncRNA1, a long non-coding RNA that is transcriptionally induced by oestrogen, promotes epithelial ovarian cancer cell proliferation.

Authors:  Jun-Jun Qiu; Xiao-Dan Zhang; Xiao-Yan Tang; Ting-Ting Zheng; Ying Zhang; Ke-Qin Hua
Journal:  Int J Oncol       Date:  2017-06-07       Impact factor: 5.650

2.  Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells.

Authors:  Yuan Li; Shengkai Huang; Yan Li; Weilong Zhang; Kun He; Mei Zhao; Hong Lin; Dongdong Li; Honggang Zhang; Zhaoxu Zheng; Changzhi Huang
Journal:  Tumour Biol       Date:  2016-08-23

3.  Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.

Authors:  Laura Devis; Cristian P Moiola; Nuria Masia; Elena Martinez-Garcia; Maria Santacana; Tomita Vasilica Stirbat; Françoise Brochard-Wyart; Ángel García; Francesc Alameda; Silvia Cabrera; Jose Palacios; Gema Moreno-Bueno; Miguel Abal; William Thomas; Sylvie Dufour; Xavier Matias-Guiu; Anna Santamaria; Jaume Reventos; Antonio Gil-Moreno; Eva Colas
Journal:  J Pathol       Date:  2017-01-23       Impact factor: 7.996

4.  Long non-coding RNA MEG3 inhibits cell growth of gliomas by targeting miR-93 and inactivating PI3K/AKT pathway.

Authors:  Ling Zhang; Xin Liang; Yuxiong Li
Journal:  Oncol Rep       Date:  2017-08-03       Impact factor: 3.906

5.  Expression of cell adhesion molecules and prognosis in breast cancer.

Authors:  S Saadatmand; E M de Kruijf; A Sajet; N G Dekker-Ensink; J G H van Nes; H Putter; V T H B M Smit; C J H van de Velde; G J Liefers; P J K Kuppen
Journal:  Br J Surg       Date:  2012-11-22       Impact factor: 6.939

6.  miRcode: a map of putative microRNA target sites in the long non-coding transcriptome.

Authors:  Ashwini Jeggari; Debora S Marks; Erik Larsson
Journal:  Bioinformatics       Date:  2012-06-19       Impact factor: 6.937

7.  CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer.

Authors:  Jiayi Wang; Xiangfan Liu; Huacheng Wu; Peihua Ni; Zhidong Gu; Yongxia Qiao; Ning Chen; Fenyong Sun; Qishi Fan
Journal:  Nucleic Acids Res       Date:  2010-04-27       Impact factor: 16.971

8.  miRTarBase: a database curates experimentally validated microRNA-target interactions.

Authors:  Sheng-Da Hsu; Feng-Mao Lin; Wei-Yun Wu; Chao Liang; Wei-Chih Huang; Wen-Ling Chan; Wen-Ting Tsai; Goun-Zhou Chen; Chia-Jung Lee; Chih-Min Chiu; Chia-Hung Chien; Ming-Chia Wu; Chi-Ying Huang; Ann-Ping Tsou; Hsien-Da Huang
Journal:  Nucleic Acids Res       Date:  2010-11-10       Impact factor: 16.971

9.  Construction and investigation of lncRNA-associated ceRNA regulatory network in papillary thyroid cancer.

Authors:  Yangjing Zhao; Hui Wang; Chengjiang Wu; Meina Yan; Haojie Wu; Jingzhe Wang; Xinxin Yang; Qixiang Shao
Journal:  Oncol Rep       Date:  2018-01-10       Impact factor: 3.906

10.  A long non-coding RNA signature to improve prognosis prediction of colorectal cancer.

Authors:  Ye Hu; Hao-Yan Chen; Chen-Yang Yu; Jie Xu; Ji-Lin Wang; Jin Qian; Xi Zhang; Jing-Yuan Fang
Journal:  Oncotarget       Date:  2014-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.